Skip to search formSkip to main contentSkip to account menu

1.2 ML hyaluronidase, ovine 200 UNT/ML Injection [Vitrase]

Known as: HYALURONIDASE (VITRASE) 200UNIT/ML INJ [VA Product], Vitrase 200 UNT/ML per 1.2 ML Injection, HYALURONIDASE, OVINE 200 [USP'U] in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [VITRASE] 
National Institutes of Health

Related topics

Related topics

12 relations
Dibasic potassium phosphateGlycoside HydrolasesHyaluronidaseInjection

Broader (1)

Miscellaneous chemical agent

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
The Use of Ovine Hyaluronidase (Vitrase®) in Non-Clearing Vitreous Hemorrhage of Varying Durations
2007
2007
Intravitreal Bevacizumab as an Adjunct to Ovine Hyaluronidase (Vitrase®) in the Long-Term Management of Vitreous Hemorrhage
2006
2006
The Compatibility of Vitrase® Combined with Kenalog®
2006
2006
Use of Vitrase® for Vitreous Hemorrhage in Non–Surgical Candidates
2004
2004
Ovine Hyaluronidase (Vitrase®, an investigational drug) Reduces Vitreous Hemorrhage Density (RVHD) and improves Best Corrected Visual Acuity (BCVA): Integrated results from 2 Phase III studies
2004
2004
Vitrase® (Ovine Hyaluronidase), an investigational drug, for the treatment of vitreous hemorrhage: safety evaluation from two large Phase III studies
2002
2002
Vitrase ISTA Pharmaceuticals.
Vitrase is under development by ISTA Pharmaceuticals Inc (formerly Advanced Corneal Systems, ACS) and Otsuka Pharmaceutical (in… 
2002
2002
Effect of Intravitreous Hyaluronidase (Vitrase®) on Progression of Diabetic Retinopathy in Humans
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)